Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mono PharmacareNSE:MONOPHARMA +4.88%9 Days Payable is 69.82 as of Sep. 2025, which is 157% above its 10-year median of 27.14. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 608 Healthcare Providers & Services companies, Mono Pharmacare ranks better than 50.66% on this metric.
The historical rank and industry rank for Mono Pharmacare's Days Payable or its related term are showing as below:
NSE:MONOPHARMA'
s Days Payable Range Over the Past 10 Years
Min: 17.24 Med: 27.14 Max: 58.3
Current: 58.3
During the past 5 years, Mono Pharmacare's highest Days Payable was 58.30. The lowest was 17.24. And the median was 27.14.
NSE:MONOPHARMA's Days Payable is ranked better than 50.66% of 608
companies
in the Healthcare Providers & Services industry
Industry Median: 57.32
vs NSE:MONOPHARMA: 58.30
Mono Pharmacare's Days Payable
increased
from Sep. 2024 (31.02) to Sep. 2025 (69.82).
It may suggest that Mono Pharmacaredelayed paying its suppliers.
Mono Pharmacare Days Payable Related Terms
Mono Pharmacare Days Payable Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare Days Payable Competitor Comparison
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Days Payable distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Mono Pharmacare's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Days Payable of 69.82 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mono Pharmacare and its competitors. This is 157% above median its historical median of 27.14. Over the past decade, Mono Pharmacare's Days Payable has ranged from 17.24 to 58.30. According to the industry distribution chart, Mono Pharmacare ranks #300 out of 608 companies in the Healthcare Providers & Services industry, placing it in the top 49.3%.
Is Mono Pharmacare's Days Payable too high?
Mono Pharmacare's current Days Payable of 69.82 is 157% above median its 10-year median of 27.14. Over the past 10 years, this metric has ranged from a low of 17.24 to a high of 58.30. The Healthcare Providers & Services industry median Days Payable is 57.32. Mono Pharmacare's value of 69.82 is 21.8% above this industry median. Based on the distribution chart, Mono Pharmacare ranks #300 out of 608 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Days Payable compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #300 out of 608 companies for Days Payable. This puts Mono Pharmacare in the upper half of its industry. The industry median Days Payable is 57.32. Mono Pharmacare's value of 69.82 is 21.8% above this benchmark. Historically, Mono Pharmacare's own Days Payable has ranged from 17.24 to 58.30 over the past decade. While the company's 10-year median is 27.14 vs. the industry median of 57.32, Mono Pharmacare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.32, based on 608 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mono Pharmacare's current Days Payable of 69.82 is 21.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current Days Payable is 69.82, which is 157% above median its own 10-year median of 27.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Days Payable of 69.82. The current Days Payable is 69.82, which is 157% above median its 10-year median of 27.14 and 21.8% above the Healthcare Providers & Services industry median of 57.32. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Days Payable is 69.82 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
